Application of the combination of eravacycline and cefepime in the preparation of a drug for resisting CRAB infection or inhibiting CRAB drug resistance

CN122681880BActive Publication Date: 2026-11-03THE SECOND PEOPLES HOSPITAL OF SHANDONG PROVINCE (SHANDONG PROVINCIAL EAR NOSE & THROAT HOSPITAL SHANDONG PROVINCIAL INST OF EAR NOSE & THROAT)
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611141427.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2026-07-30
Publication Date
2026-11-03
Estimated Expiration
2046-07-30

AI Technical Summary

Technical Problem

Existing drug combinations are not effective in treating carbapenem-resistant Acinetobacter baumannii (CRAB) infections and are prone to inducing drug resistance, thus lacking effective combination therapy strategies.

Method used

Iracycline and cefepime are used in combination at a mass ratio of 1:16 to prepare drugs against CRAB infection or to inhibit CRAB resistance, in combination with medically acceptable carriers such as phosphate buffer, saline or water.

Benefits of technology

It significantly improves the antibacterial and bactericidal effects against CRAB, reduces the risk of drug resistance development, enhances the therapeutic effect on CRAB infection, and has excellent synergistic antibacterial effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122681880B_ABST
    Figure CN122681880B_ABST
Patent Text Reader

Abstract

The application belongs to the technical field of biological medicine, and particularly relates to application of elacin combined with cefepime in preparation of a drug for resisting CRAB infection or inhibiting CRAB drug resistance, and the mass ratio of elacin to cefepime is 1:16. It is proved by in-vitro experiments that the MIC of elacin combined with cefepime to CRAB can be reduced to 1 / 4 of the MIC of single drug, and the combination has excellent in-vitro antibacterial and bactericidal activity to CRAB and can inhibit the development of CRAB drug resistance. Meanwhile, it is proved by animal experiments that the combination of elacin and cefepime can improve the survival rate of cressida moth larvae after infection with CRAB, and significantly reduces the tissue damage caused by CRAB infection in the cressida moth larvae, and has excellent anti-CRAB infection effect, thereby providing a high-efficiency, long-term applicable clinical alternative treatment scheme for CRAB infection.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Novel antibacterial 3"-derivatives of 4,6-disubstituted 2,5-dideoxystreptamine aminoglycoside antibiotics

    CN113710682A

  • Application of cefepime avibactam

    CN116473976A